Advertisement
Screener

ATARA BIOTHERAPEUTICS, INC. (ATRA) Increase (Decrease) in Other Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

ATARA BIOTHERAPEUTICS, INC. Increase (Decrease) in Other Accrued Liabilities

ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Increase (Decrease) in Other Accrued Liabilities of $1.10 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2017-11-09

  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2017-09-30 was $944.00K, a 376.77% increase year-over-year.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2017-06-30 was -$19.00K.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2017-03-31 was $179.00K, a 73.24% decline year-over-year.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2016-12-31 was -$218.00K, a 826.67% decline year-over-year.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other accrued liabilities for fiscal 2016 was $215.00K, a 26.62% decline from fiscal 2015.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other accrued liabilities for fiscal 2015 was $293.00K, a 7225.00% increase from fiscal 2014.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other accrued liabilities for fiscal 2014 was $4.00K, a 96.15% decline from fiscal 2013.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other accrued liabilities for fiscal 2013 was $104.00K.
Period endIncrease (Decrease) in Other Accrued Liabilities 3 monthIncrease (Decrease) in Other Accrued Liabilities 3 month as first filedIncrease (Decrease) in Other Accrued Liabilities 4 monthIncrease (Decrease) in Other Accrued Liabilities 6 monthIncrease (Decrease) in Other Accrued Liabilities 9 monthIncrease (Decrease) in Other Accrued Liabilities 9 month as first filedIncrease (Decrease) in Other Accrued Liabilities 12 monthIncrease (Decrease) in Other Accrued Liabilities 12 month as first filed
2017-09-30$944.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
$925.00K
derived: sum of 2 quarters · filed 2017-11-09
$1.10M
10-Q · filed 2017-11-09
$886.00K
derived: sum of 4 quarters · filed 2017-11-09
2017-06-30-$19.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07
$160.00K
10-Q · filed 2017-08-07
-$58.00K
derived: sum of 3 quarters · filed 2017-08-07
$140.00K
derived: sum of 4 quarters · filed 2017-11-09
2017-03-31$179.00K
10-Q · filed 2017-05-04
-$39.00K
derived: sum of 2 quarters · filed 2017-05-04
$159.00K
derived: sum of 3 quarters · filed 2017-11-09
-$275.00K
derived: sum of 4 quarters · filed 2017-11-09
2016-12-31-$218.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09
-$20.00K
derived: sum of 2 quarters · filed 2017-11-09
-$454.00K
derived: sum of 3 quarters · filed 2017-11-09
$215.00K
10-K · filed 2017-03-09
2016-09-30$198.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
-$236.00K
derived: sum of 2 quarters · filed 2017-11-09
$433.00K
10-Q · filed 2017-11-09
$463.00K
derived: sum of 4 quarters · filed 2017-11-09
2016-06-30-$434.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07
$235.00K
10-Q · filed 2017-08-07
$265.00K
derived: sum of 3 quarters · filed 2017-08-07
-$2.72M
derived: sum of 4 quarters · filed 2017-08-07
2016-03-31$669.00K
10-Q · filed 2017-05-04
$699.00K
derived: sum of 2 quarters · filed 2017-05-04
-$2.29M
derived: sum of 3 quarters · filed 2017-05-04
$733.00K
derived: sum of 4 quarters · filed 2017-05-04
2015-12-31$30.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09
-$2.95M
derived: sum of 2 quarters · filed 2017-03-09
$64.00K
derived: sum of 3 quarters · filed 2017-03-09
$293.00K
10-K · filed 2017-03-09
2015-09-30-$2.98M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04
$34.00K
derived: sum of 2 quarters · filed 2016-11-04
$263.00K
10-Q · filed 2016-11-04
$1.98M
10-Q · filed 2015-11-06
-$173.00K
derived: sum of 4 quarters · filed 2017-03-09
2015-06-30$3.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08
$3.25M
10-Q · filed 2016-08-08
$2.81M
derived: sum of 3 quarters · filed 2017-03-09
$2.90M
derived: sum of 4 quarters · filed 2017-03-09
2015-03-31$229.00K
10-Q · filed 2016-05-06
$1.14M
10-Q · filed 2015-05-11
-$207.00K
derived: sum of 2 quarters · filed 2017-03-09
-$122.00K
derived: sum of 3 quarters · filed 2017-03-09
-$324.00K
derived: sum of 4 quarters · filed 2017-03-09
2014-12-31-$436.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09
-$351.00K
derived: sum of 2 quarters · filed 2017-03-09
-$553.00K
derived: sum of 3 quarters · filed 2017-03-09
$4.00K
10-K · filed 2017-03-09
$626.00K
10-K · filed 2015-02-26
2014-09-30$85.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06
-$117.00K
derived: sum of 2 quarters · filed 2015-11-06
$440.00K
10-Q · filed 2015-11-06
$2.00K
derived: sum of 4 quarters · filed 2016-03-04
2014-06-30-$202.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07
$355.00K
10-Q · filed 2015-08-07
-$83.00K
derived: sum of 3 quarters · filed 2016-03-04
2014-03-31$557.00K
10-Q · filed 2015-05-11
$119.00K
derived: sum of 2 quarters · filed 2016-03-04
2013-12-31-$438.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-04
$104.00K
10-K · filed 2016-03-04
$312.00K
10-K · filed 2015-02-26
2013-09-30$542.00K
10-Q · filed 2014-11-12
2012-12-31$120.00K
10-K · filed 2015-02-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
Vaxart, Inc. (VXRT)United States$0.080B3.84
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02
BioStem Technologies, Inc. (BSEM)United States$0.069B
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37